Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

y Rat Neurons by a GABA-Independent Pathway in presentation P-192. About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the United States Food and Drug Administration, European Medicines Agency and Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit our Web Site at: www.neurochem.com.

This news release contains forward-looking statements regarding tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that ac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug

Post Your Comments:
(Date:11/9/2009)...ov. 9 Access MediQuip, LLC, the na...plantable medical device management solutions to t... relocating its corporate headquarters to Lake Mar...inued rapid growth, includes a major expansion of ... open in January 2010 and relocation and expansion...
(Date:11/9/2009).... 9 RBC Life Sciences,...proprietary nutritional supplements and wound care...he Top 100 workplaces in the Dallas-Fort Worth are...he Top 100 Places to Work 2009 competition surveye... medium and large firms throughout the DFW metropo...
(Date:11/9/2009)... 9 Arcadia Resources, In...ative consumer health care services under the Arca...ldsmith to its Board of Directors. Goldsmith will...rom the Board. ,, (Photo: http://www.newsc...dsmith is the Daniel Paul Professor of Government ...
Breaking Medicine Technology:Access MediQuip Moves Company Headquarters to Lake Mary, Florida 2RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas-Fort Worth Area 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 1Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 2Nottingham scientists commissioned for urgent swine flu research 55306 1Nottingham scientists commissioned for urgent swine flu research 55306 2New study suggests the brain predicts what eyes in motion will see 55304 1New study suggests the brain predicts what eyes in motion will see 55304 2
...(BUSINESS WIRE)--Apr 30, 2007 - Insmed Inc.,(Nasd...hase II,investigator-sponsored clinical study of t...ts affected with HIV-associated,Adipose Redistribu...e study, being conducted at the,University of Cali... 0.5 mg/kg/day IPLEX treatment in seven patients i...
...Y, England, April 30, 2007 /PRNewswire-FirstCall/,...reading to the,lungs, the brain or the bone which ...lised to the breast , Newly published data in the ... Press show that after two years of post-surgical,...ve early breast,cancer treated with Femara experie...
Other Medicine Technology:Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 2Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 3Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 4Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 2Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 3Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 4Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 5
(Date:11/10/2009)... It is now possible to achieve exceptionally s...sed of hard materials such as ceramics, carbide an...h the new Diamond Flex-Hone® honing tool fro... Los Angeles (PRWEB) November 10, 2009 -- Usi...edded to the ends of flexible filaments, the Diamo...
(Date:11/10/2009)... Carrington Nuamah, P.C., a Seattle law firm p... and estate law, has unveiled a new website. Resi...learn more about the firm at www.carringtonnuamah...is Nexis) November 10, 2009 -- Seattle Law Firm Ca...t www.carringtonnuamah.com . Lawyers Andrew Carr...
(Date:11/10/2009)...ersity Rollins School of Public Health researchers...American Public Health Association,s annual meetin... compliance with national recommendations that a p...tes of their arrival to the Emergency Department (...s from Emory scientists are highlighted below. , ...
(Date:11/9/2009)... Tarkett Sports, the worldwide leader in sport...oduct offering with a more complete and innovative...ndoor sports flooring experts and the launch of w... (PRWEB) November 9, 2009 -- Tarkett Sports, ...ooring products includes hardwood and synthetic ba...
(Date:11/9/2009)... on Election Promise. Now Is Time for Senate to Ac.../ -- The following is a statement by Anna Burger, ...truggle and decades of delay, the U.S. House of Re...ss historic reform legislation to assure every Ame... quality, affordable health care. The House,s acti...
Breaking Medicine News(10 mins):Health News:Diamond Honing Tool Technology: The New Standard in Surface Finishing of Hard Materials 2Health News:Seattle Law Firm Carrington Nuamah Launches New Website for Personal Injury, Bankruptcy, Immigration and Estate Law 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2Health News:Tarkett Sports Launches Revamped Indoor Sports Flooring Division and New Indoor Website 2Health News:Statement of Anna Burger, Chair, Change to Win, on U.S. House Vote for Health Care Reform 2
..., VA Researchers have developed a series of tests...rmality of taste (gustatory function) and smell (o... a new study published in the July 2008 edition of...ority of 16 different test odorants that can measu...
...eive Grants as 4th & 5th Graders ,Walked the Walk ...dhood Obesity Campaign, - Campaign Addresses Futu... Children Are Obese, ORANG...essful participation in the Sixth,Annual KID HEALT...
...nce in the Dallas-Fort Worth market, NORTH HOLLYW... Inc. (Nasdaq: IPCM ), a leading national physici... has acquired Texas,Inpatient Services (T.I.P.S.)....ion of,T.I.P.S. continues to strengthen IPC,s posi...
..., June 30 Smart Balance, Inc.,(Nasdaq: SMBL ) an...ad-market Russell 2000(R) and Russell 3000(R) inde...ensive set of U.S. and global equity,indexes on Ju...investors," said Robert S. Gluck, Vice Chairman an...
...tion seeks policy, social changes that boost healt... (HealthDay News) -- Reducing the high rate of obe..., population-based strategy, says a new American H...ng right and being physically active. , About 67 m...
...t liver transplantation reliably yield grafts for ...de new findings about the procedure in the July is...Wiley & Sons. The articles are also available onli...ties for those in need of a transplant. An example...
Other Medicine News:Health News:So. Calif. Schools Receive $14,500 From KID HEALTHY -- Steps To Healthy Living Campaign! 2Health News:So. Calif. Schools Receive $14,500 From KID HEALTHY -- Steps To Healthy Living Campaign! 3Health News:IPC The Hospitalist Company Acquires Texas Inpatient Services 2Health News:Smart Balance Added to Russell 2000 and 3000 Indexes 2Health News:Population-Based Strategy Urged to Cut U.S. Obesity Rate 2Health News:Experts examine challenges of split liver transplantation 2
SLM 4000 Autolensmeter
CL-100 4.0 Computerized Lensmeter
Pro-lll
FF 450plus Iru
Medicine Products: